Influence of drug formulation on OATP1B-mediated transport of paclitaxel

Cancer Research

Volumn 74, Issue 11, 2014, Pages 3137-3145

  Nieuweboer, Annemieke J M ^a   Hu, Shuiying ^b   Gui, Chunshan ^c   Hagenbuch, Bruno ^c   Moghaddam Helmantel, Inge M Ghobadi ^a   Gibson, Alice A ^b   De Bruijn, Peter ^a   Mathijssen, Ron H J ^a   Sparreboom, Alex ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; CREMOPHOR; DOCETAXEL; ORGANIC ANION TRANSPORTER B; PACLITAXEL; POLYSORBATE 80; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; TAXANE; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LIVER CLEARANCE; MOUSE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN INTERACTION; TRANSPORT KINETICS; ANIMAL; CELL LINE; CHO CELL LINE; CRICETULUS; DBA MOUSE; DRUG EFFECTS; DRUG INTERACTION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; LIVER; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; XENOPUS LAEVIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BRIDGED COMPOUNDS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETULUS; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; LIVER; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; OOCYTES; ORGANIC ANION TRANSPORTERS; PACLITAXEL; TAXOIDS; TISSUE DISTRIBUTION; XENOPUS LAEVIS;

EID: 84902138738     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3634     Document Type: Article

References (49)

1. Zhang Z, Mei L, Feng SS. Paclitaxel drug delivery systems. Expert Opin Drug Deliv 2013;10:325-40.
2. Tan Q, Liu X, Fu X, Li Q, Dou J, Zhai G. Current development in nanoformulations of docetaxel. Expert Opin Drug Deliv 2012;9: 975-90.
3. Vrignaud P, Semiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013;19: 2973-83.
4. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
5. Hennenfent KL, Govindan R. Novel formulations of taxanes: A review. Old wine in a new bottle? Ann Oncol 2006;17:735-49.
6. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996;56:2112-5.
7. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47: 309-18.
8. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
9. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81:330-5.
10. Ait-Oudhia S, Straubinger RM, Mager DE. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res 2012;29:2833-44.
11. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001;19:4065-73.
12. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 2005;44:349-66.
13. Ellis AG, Webster LK. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 1999;43:13-8.
14. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:815-8.
15. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 2013;19:821-32.
16. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82.
17. van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 2011;17:294-301.
18. Konig J, Muller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 2013;65:944-66.
19. Engel A, Oswald S, Siegmund W, Keiser M. Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm 2012;9:2577-81.
20. Hagenbuch B, Stieger B. The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 2013;34:396-412.
21. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18:4433-40.
22. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, et al. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 2008;584:57-65.
23. de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, et al. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding. J Pharm Biomed Anal 2012;59: 117-22.
24. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006;5:833-9.
25. Kaliss N, Pressman D. Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins. Proc Soc Exp Biol Med 1950;75:16-20.
26. Gui C, Wahlgren B, Lushington GH, Hagenbuch B. Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17b-glucuronide transport. Pharmacol Res 2009;60:50-6.
27. Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006;91:140-9.
28. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, et al. Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008;260:163-9.
29. Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 2011;65:417-26.
30. Takano M, Otani Y, Tanda M, Kawami M, Nagai J, Yumoto R. Paclitaxel- resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab Pharmacokinet 2009;24:418-27.
31. Tanino T, Nawa A, Nakao M, Noda M, Fujiwara S, Iwaki M. Organic anion transporting polypeptide 2-mediated uptake of paclitaxel and 20- ethylcarbonate-linked paclitaxel in freshly isolated rat hepatocytes. J Pharm Pharmacol 2009;61:1029-35.
32. Desai N, De T, Ci S, Louie L, Trieu V. Characterization and in vitro/in vivo dissolution of nab-paclitaxel nanoparticles. AACR Meeting Abstracts 2008;2008:5624.
33. Yeh TK, Lu Z, Wientjes MG, Au JL. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22:867-74.
34. van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999;5: 2918-24.
35. Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 2008;74:320-9.
36. Walker AL, Lancaster CS, Finkelstein D, Ware RE, Sparreboom A. Organic anion transporting polypeptide 1B (OATP1B) transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol 2013;305:C1223-9.
37. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
38. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008;14: 4200-5.
39. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165:1260-87.
40. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012;33:100-8.
41. Muller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011;12:1017-37.
42. Zolk O, Fromm MF. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther 2011;89:798-805.
43. Fahrmayr C, Konig J, Auge D, Mieth M, Fromm MF. Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCKOATP1B1- UGT1A1-MRP2 cells. Br J Pharmacol 2012;165: 1836-47.
44. Izquierdo MA, Garcia M, Ponton JL, Martinez M, Valenti V, Navarro M, et al. A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. Eur J Cancer 2006;42:1789-96.
45. Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 2013;12:1537-44.
46. Fujita KI, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, et al. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 2014;31: 204-15.
47. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclit axel. Clin Cancer Res 2006;12:1317-24.
48. Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, et al. SPARC independent drug delivery and antitumour effects of nabpaclitaxel in genetically engineered mice. Gut 2013 Sep 25. [Epub ahead of print].
49. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release 2013;170:365-72.